CTLA4 and nonpapillary renal cell carcinoma: Given that ipilimumab, a humanized IgG1 monoclonal antibody against CTLA-4, is already used as a standard of care in ccRCC [155], CTLA-4-targeted NIR-PIT may find a role in the treatment of ccRCC.